These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 36840914)

  • 41. Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China.
    Liu G; Kang S
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):85-91. PubMed ID: 33627014
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China.
    Shang F; Zhang B; Kang S
    Expert Rev Pharmacoecon Outcomes Res; 2023 Mar; 23(3):337-343. PubMed ID: 36655382
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer.
    Ding D; Hu H; Li S; Zhu Y; Shi Y; Liao M; Liu J; Tian X; Liu A; Huang J
    J Natl Compr Canc Netw; 2021 Aug; 19(10):1141-1147. PubMed ID: 34348237
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA.
    Ionova Y; Vuong W; Sandoval O; Fong J; Vu V; Zhong L; Wilson L
    Clin Drug Investig; 2022 Jun; 42(6):491-500. PubMed ID: 35604530
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Avelumab Maintenance Treatment After First-line Chemotherapy in Advanced Urothelial Carcinoma-A Cost-Effectiveness Analysis.
    Lin D; Luo S; Lin S; Zhong L; Zhou W; Gu D; Huang X; Chen Q; Xu X; Weng X
    Clin Genitourin Cancer; 2023 Feb; 21(1):8-15. PubMed ID: 36328903
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China.
    Liu Q; Luo X; Peng L; Yi L; Wan X; Zeng X; Tan C
    BMJ Open; 2020 Nov; 10(11):e040691. PubMed ID: 33243806
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China.
    Zhang M; Xu K; Lin Y; Zhou C; Bao Y; Zhang L; Li X
    Front Immunol; 2023; 14():1169752. PubMed ID: 37313403
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness analysis of durvalumab, tremelimumab, and etoposide-platinum in first-line treatment of extensive-stage small cell lung cancer.
    Meng M; Liu X; Liang X; Chen X; Li Y
    Medicine (Baltimore); 2024 Apr; 103(16):e37836. PubMed ID: 38640325
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biomarkers-Based Cost-Effectiveness of Toripalimab Plus Chemotherapy for Patients with Treatment-Naive Advanced Non-Small Cell Lung Cancer.
    Zhang H; Li L; Feng L; Zhou Z; Zhang X; Feng J; Liu Q
    Adv Ther; 2023 Nov; 40(11):4945-4956. PubMed ID: 37715852
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC.
    Chen P; Wang X; Zhu S; Li H; Rui M; Wang Y; Sun H; Ma A
    Front Public Health; 2022; 10():956792. PubMed ID: 36016894
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness analysis of atezolizumab in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen: a United Kingdom health care perspective.
    Jiang Y; Zhao M; Xi J; Li J; Tang W; Zheng X
    Front Public Health; 2023; 11():1282374. PubMed ID: 37841712
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2- Advanced Breast Cancer in the USA?
    Wu W; Lin H; Cai J; Sun H; Liu J; Hu C; Wei X
    Clin Drug Investig; 2023 Dec; 43(12):939-948. PubMed ID: 37975961
    [TBL] [Abstract][Full Text] [Related]  

  • 53. First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis.
    Zhu Y; Hu H; Ding D; Li S; Liao M; Shi Y; Huang J
    Cost Eff Resour Alloc; 2021 Dec; 19(1):77. PubMed ID: 34863203
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US.
    Wang Y; Rui M; Yang L; Wang X; Shang Y; Ma A; Li H
    Front Public Health; 2021; 9():650392. PubMed ID: 33889559
    [No Abstract]   [Full Text] [Related]  

  • 55. Cost-effectiveness analysis of sugemalimab in combination with chemotherapy as first-line treatment in Chinese patients with metastatic NSCLC.
    Chen P; Li Y; Jing X; Chen J; Chen S; Yang Q
    Lung Cancer; 2022 Dec; 174():157-164. PubMed ID: 36413882
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives.
    Wan XM; Peng LB; Ma JA; Li YJ
    Cancer; 2017 Jul; 123(14):2634-2641. PubMed ID: 28301684
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
    Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
    J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
    [No Abstract]   [Full Text] [Related]  

  • 58. Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma.
    Shao T; Zhao M; Tang W
    Front Oncol; 2022; 12():953671. PubMed ID: 36561521
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A cost-effectiveness analysis of the combination of serplulimab with chemotherapy for advanced esophageal squamous cell carcinoma: insights from the ASTRUM-007 trial.
    Li J; Xu C; Yuan S
    Cost Eff Resour Alloc; 2024 Jan; 22(1):8. PubMed ID: 38281053
    [TBL] [Abstract][Full Text] [Related]  

  • 60. First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China.
    Li LY; Wang H; Chen X; Li WQ; Cui JW
    Chin Med J (Engl); 2019 Dec; 132(23):2790-2794. PubMed ID: 31856049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.